Skip to main content
Premium Trial:

Request an Annual Quote

America's Choice Provider Network to Cover CombiMatrix's Molecular Dx Testing Services

NEW YORK (GenomeWeb News) – America's Choice Provider Network will now cover CombiMatrix's diagnostic laboratory services, CombiMatrix said today.

ACPN is a San Diego-based company that facilitates out-of-network services for more than 540 payers in the US, reaching about 14 million people. Under the new agreement, individuals whose healthcare providers liaise with ACPN will now have access to CombiMatrix's menu of chromosomal microarray-based prenatal, pediatric, and cancer cytogenetic testing services.

In addition to CMA, Irvine, Calif.-based CombiMatrix also offers fluorescence in situ hybridization, PCR and G-band chromosome analyses.

The firm, which saw its third quarter revenues rise 15 percent on increased prenatal testing volumes, has announced a number of payor agreements this year. Earlier this month, it announced a deal with Blue Cross and Blue Shield of Kansas City. In October, CombiMatrix said it had reached a deal with Three Rivers Provider Network, and during the summer it inked an agreement with Blue Shield of California.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.